H1 revenue up 54%, standalone profit rises 80%

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

ACUTAAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+13.3%Reaction day

₹3349.30

prior close

₹3486.40

announcement price

In-mkt

timing

Nifty Smallcap 250market+2.2%+11.1% vs market

Pharmaceuticals peers, median of 173sector+2.0%+11.4% vs sector

On the reaction day the stock moved 11.1 pts more than Nifty Smallcap 250 and 11.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.5

10m

+2.2

15m

+3.8

30m

+6.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+13.3+2.2+11.1+2.0+11.4

Next day

+10.2+2.5+7.6+2.6+7.5

+17.6+3.2+14.4+2.6+15.0

+19.7pendingpending+1.9+17.8

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the half year ended September 30, 2026, consolidated revenue was Rs 788.59 crore, up 53.6% from Rs 513.33 crore. Standalone profit after tax rose 80.1% to Rs 211.63 crore from Rs 117.54 crore. Consolidated operating cash flow was Rs 215.92 crore. The auditor's limited review had no modifications.

Likely market impact

Higher revenue, profit and operating cash flow are positive for shareholders, though the figures are unaudited and may change before the annual audit.